PDF(Pubmed)
Abstract：
UNASSIGNED: To evaluate the perioperative as well as early oncological outcomes of patients undergoing robotic retroperitoneal lymph node dissection for treatment of testicular cancer.
UNASSIGNED: We conducted a prospective consecutive case series of patients undergoing robotic assisted retroperitoneal lymph node dissection for metastatic testicular cancer between May 2018 and July 2021 at our institution. Data were collected on patient and tumour characteristics, intraoperative and postoperative parameters, and functional and oncological outcomes. Descriptive statistics are presented.
UNASSIGNED: Nineteen patients were identified; 18 (94.7%) completed the procedure robotically and one was converted to open surgery; 78.9% of patients had stage ≥IIB and 12 (63.2%) patients had undergone prior chemotherapy. The median operative time was 300 (interquartile range [IQR] 240-315) min. Median blood loss was 100 (IQR 50-175) mL. Median length of stay was 2 (range 1-11) days. All robotically completed patients commenced diet and passed flatus on Day 1 and were discharged by Day 3. The median lymph node yield was 40.5 (IQR 38-51) nodes. All patients undergoing nerve-sparing procedures recovered antegrade ejaculatory function. One patient had a Clavien-Dindo III complication (chylous ascites requiring drainage). At a median follow-up of 22.3 (IQR 16.3-24.9) months, one patient developed retroperitoneal recurrence, which was successfully treated with second-line chemotherapy; no other patients have had recurrences.
UNASSIGNED: Robotic retroperitoneal lymph node dissection is a safe and feasible alternative to open surgery in appropriately selected patients, offering low morbidity. Early oncological outcomes are promising. Larger cohorts and longer follow-ups are required to validate our institution\'s findings.
UNASSIGNED: We conducted a prospective consecutive case series of patients undergoing robotic assisted retroperitoneal lymph node dissection for metastatic testicular cancer between May 2018 and July 2021 at our institution. Data were collected on patient and tumour characteristics, intraoperative and postoperative parameters, and functional and oncological outcomes. Descriptive statistics are presented.
UNASSIGNED: Nineteen patients were identified; 18 (94.7%) completed the procedure robotically and one was converted to open surgery; 78.9% of patients had stage ≥IIB and 12 (63.2%) patients had undergone prior chemotherapy. The median operative time was 300 (interquartile range [IQR] 240-315) min. Median blood loss was 100 (IQR 50-175) mL. Median length of stay was 2 (range 1-11) days. All robotically completed patients commenced diet and passed flatus on Day 1 and were discharged by Day 3. The median lymph node yield was 40.5 (IQR 38-51) nodes. All patients undergoing nerve-sparing procedures recovered antegrade ejaculatory function. One patient had a Clavien-Dindo III complication (chylous ascites requiring drainage). At a median follow-up of 22.3 (IQR 16.3-24.9) months, one patient developed retroperitoneal recurrence, which was successfully treated with second-line chemotherapy; no other patients have had recurrences.
UNASSIGNED: Robotic retroperitoneal lymph node dissection is a safe and feasible alternative to open surgery in appropriately selected patients, offering low morbidity. Early oncological outcomes are promising. Larger cohorts and longer follow-ups are required to validate our institution\'s findings.
摘要：
■评估接受机器人腹膜后淋巴结清扫术治疗睾丸癌患者的围手术期和早期肿瘤学结果。
■我们在2018年5月至2021年7月期间在我们机构进行了一系列前瞻性连续病例，这些患者接受机器人辅助腹膜后淋巴结清扫术治疗转移性睾丸癌。收集了有关患者和肿瘤特征的数据，术中和术后参数，以及功能和肿瘤结果。提供描述性统计数据。
■确认了19例患者；18例（94.7%）通过机器人完成手术，1例转为开放手术；78.9%的患者≥IIB期，12例（63.2%）患者曾接受过化疗。中位手术时间为300（四分位距[IQR]240-315）分钟。中位失血量为100(IQR50-175)mL。中位住院时间为2天（范围1-11天）。所有机器人完成的患者在第1天开始饮食并通过肠胃排气，并在第3天出院。中位淋巴结产量为40.5(IQR38-51)个节点。所有接受神经保留手术的患者均恢复了顺行射精功能。一名患者患有Clavien-DindoIII并发症（乳糜腹水需要引流）。中位随访时间为22.3个月（IQR16.3-24.9个月），一名患者出现腹膜后复发,经二线化疗成功治疗;没有其他患者复发。
■机器人腹膜后淋巴结清扫术在适当选择的患者中是一种安全可行的替代方法，提供低发病率。早期肿瘤结果是有希望的。需要更大的队列和更长时间的随访来验证我们机构的发现。
■我们在2018年5月至2021年7月期间在我们机构进行了一系列前瞻性连续病例，这些患者接受机器人辅助腹膜后淋巴结清扫术治疗转移性睾丸癌。收集了有关患者和肿瘤特征的数据，术中和术后参数，以及功能和肿瘤结果。提供描述性统计数据。
■确认了19例患者；18例（94.7%）通过机器人完成手术，1例转为开放手术；78.9%的患者≥IIB期，12例（63.2%）患者曾接受过化疗。中位手术时间为300（四分位距[IQR]240-315）分钟。中位失血量为100(IQR50-175)mL。中位住院时间为2天（范围1-11天）。所有机器人完成的患者在第1天开始饮食并通过肠胃排气，并在第3天出院。中位淋巴结产量为40.5(IQR38-51)个节点。所有接受神经保留手术的患者均恢复了顺行射精功能。一名患者患有Clavien-DindoIII并发症（乳糜腹水需要引流）。中位随访时间为22.3个月（IQR16.3-24.9个月），一名患者出现腹膜后复发,经二线化疗成功治疗;没有其他患者复发。
■机器人腹膜后淋巴结清扫术在适当选择的患者中是一种安全可行的替代方法，提供低发病率。早期肿瘤结果是有希望的。需要更大的队列和更长时间的随访来验证我们机构的发现。
